These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 37714381)

  • 1. Clinical and histological features under different nomenclatures of fatty liver disease: NAFLD, MAFLD, MASLD and MetALD.
    Chen L; Tao X; Zeng M; Mi Y; Xu L
    J Hepatol; 2024 Feb; 80(2):e64-e66. PubMed ID: 37714381
    [No Abstract]   [Full Text] [Related]  

  • 2. Differences in the prevalence of NAFLD, MAFLD, and MASLD according to changes in the nomenclature in a health check-up using MRI-derived proton density fat fraction.
    Park HJ; Lee S; Lee JS
    Abdom Radiol (NY); 2024 Sep; 49(9):3036-3044. PubMed ID: 38587630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deciphering metabolic dysfunction-associated steatotic liver disease: insights from predictive modeling and clustering analysis.
    Mori K; Akiyama Y; Tanaka M; Sato T; Endo K; Hosaka I; Hanawa N; Sakamoto N; Furuhashi M
    J Gastroenterol Hepatol; 2024 Jul; 39(7):1382-1393. PubMed ID: 38629681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Noninvasive tests maintain high accuracy for advanced fibrosis in chronic hepatitis B patients with different nomenclatures of steatotic liver disease.
    Chen L; Tao X; Zeng M; Li Y; Han J; Wang Y; Liu Y; Shi R; Su R; Xu L; Mi Y
    J Med Virol; 2024 Apr; 96(4):e29613. PubMed ID: 38634477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of NAFLD, MAFLD and MASLD characteristics and mortality outcomes in United States adults.
    Song R; Li Z; Zhang Y; Tan J; Chen Z
    Liver Int; 2024 Apr; 44(4):1051-1060. PubMed ID: 38293788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Analysis of non-alcoholic fatty liver disease differences from metabolic dysfunction-associated fatty liver disease based on clinical features].
    Liu YX; Guo F; Niu LN; Zhang B; Dou J; Xu Q; Ning ZH; Wang XZ
    Zhonghua Gan Zang Bing Za Zhi; 2024 Apr; 32(4):346-353. PubMed ID: 38733190
    [No Abstract]   [Full Text] [Related]  

  • 7. Steatotic liver disease-associated all-cause/cause-specific mortality in the United States.
    Kim D; Wijarnpreecha K; Cholankeril G; Ahmed A
    Aliment Pharmacol Ther; 2024 Jul; 60(1):33-42. PubMed ID: 38649335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of steatotic liver disease, MASLD, MetALD and significant fibrosis in people with HIV in the United States.
    Gawrieh S; Vilar-Gomez E; Woreta TA; Lake JE; Wilson LA; Price JC; Naggie S; Sterling RK; Heath S; Corey KE; Cachay ER; Ajmera V; Tonascia J; Sulkowski MS; Chalasani N; Loomba R
    Aliment Pharmacol Ther; 2024 Mar; 59(5):666-679. PubMed ID: 38158589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Editorial: International Consensus Recommendations to Replace the Terminology of Non-Alcoholic Fatty Liver Disease (NAFLD) with Metabolic-Associated Fatty Liver Disease (MAFLD).
    Méndez-Sánchez N; Díaz-Orozco LE
    Med Sci Monit; 2021 Jul; 27():e933860. PubMed ID: 34248137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD.
    Abdelhameed F; Kite C; Lagojda L; Dallaway A; Chatha KK; Chaggar SS; Dalamaga M; Kassi E; Kyrou I; Randeva HS
    Curr Obes Rep; 2024 Sep; 13(3):510-531. PubMed ID: 38809396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [NAFLD renaming to MAFLD, MASLD: background, similarities, differences, and countermeasures].
    Fan JG; Li XY
    Zhonghua Gan Zang Bing Za Zhi; 2023 Aug; 31(8):789-792. PubMed ID: 37723058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing similarities and differences between NAFLD, MAFLD, and MASLD in the general U.S. population.
    Zou H; Ma X; Pan W; Xie Y
    Front Nutr; 2024; 11():1411802. PubMed ID: 39040926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of nomenclature as metabolic associated steatotic liver disease on steatotic liver disease prevalence and screening: a prospective population survey in Asians.
    Wu T; Ye J; Mo S; Ye M; Li X; Li Q; Wang W; Zheng Q; Luo K; Zhang Y; Tu S; Che D; Gong R; Chen X; Miu R; Shao C; Sun Y; Zhong B
    J Gastroenterol Hepatol; 2024 Aug; 39(8):1636-1647. PubMed ID: 38695344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breaking new ground: MASLD vs. MAFLD-which holds the key for risk stratification?
    Ramírez-Mejía MM; Jiménez-Gutiérrez C; Eslam M; George J; Méndez-Sánchez N
    Hepatol Int; 2024 Feb; 18(1):168-178. PubMed ID: 38127259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From non-alcoholic fatty liver disease (NAFLD) to metabolic-associated fatty liver disease (MAFLD): A journey over 40 years.
    Kuchay MS; Misra A
    Diabetes Metab Syndr; 2020; 14(4):695-696. PubMed ID: 32442920
    [No Abstract]   [Full Text] [Related]  

  • 16. Impact of renaming NAFLD to MAFLD in an Australian regional cohort: Results from a prospective population-based study.
    Kemp W; Clayton-Chubb D; Majeed A; Glenister KM; Magliano DJ; Lubel J; Bourke L; Simmons D; Roberts SK
    J Gastroenterol Hepatol; 2022 Feb; 37(2):395-403. PubMed ID: 34693553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Steatotic liver disease predicts cardiovascular disease and advanced liver fibrosis: A community-dwelling cohort study with 20-year follow-up.
    Choe HJ; Moon JH; Kim W; Koo BK; Cho NH
    Metabolism; 2024 Apr; 153():155800. PubMed ID: 38266957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematically comparing epidemiological and clinical features of MAFLD and NAFLD by meta-analysis: Focusing on the non-overlap groups.
    Ayada I; van Kleef LA; Alferink LJM; Li P; de Knegt RJ; Pan Q
    Liver Int; 2022 Feb; 42(2):277-287. PubMed ID: 34953098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of Metabolic-Associated Fatty Liver Disease/Metabolic Dysfunction-Associated Steatotic Liver Disease: From Medication Therapy to Nutritional Interventions.
    Beygi M; Ahi S; Zolghadri S; Stanek A
    Nutrients; 2024 Jul; 16(14):. PubMed ID: 39064665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic dysfunction-associated steatotic liver disease: Evolution of the final terminology.
    Portincasa P; Baffy G
    Eur J Intern Med; 2024 Jun; 124():35-39. PubMed ID: 38653634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.